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The  development  and  progression  of  oral  squamous  cell  carcinoma  (OSCC)  is a multistep  process,  which
involves  many  genetic  factors.  Among  them,  loss  of  heterozygosity  (LOH)  studies  have  been used  to
identify  regions  on  chromosomes  that  may  contain  putative  tumor  suppressor  genes  (TSGs).  Here,  we9 November 2011
ccepted 2 December 2011
eywords:
ral squamous cell carcinoma
searched  PubMed  for relevant  publications  including  our  previous  studies  and  compared  results  of  LOH
in OSCCs  from  the  articles.  LOHs  in OSCCs  were  observed  at various  loci  on almost  all chromosomes,
except  X and  Y.  In  this  review,  the  LOH  in  patients  with  OSCC  and  the  interrelationship  between  TSGs
and  OSCC  initiation  and  progression  are  discussed.oss of heterozygosity
umor suppressor gene
© 2011 Japanese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
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. Introduction PubMed for relevant publications including our previous studies
[1–17] and compared results of LOH in OSCCs from the articles.The development and progression of oral squamous cell carci-
oma (OSCC) is a multistep process, which involves many genetic
actors. Among them, loss of heterozygosity (LOH) studies have
een used to identify regions on chromosomes that may  con-
ain putative tumor suppressor genes (TSGs). Here, we searched
∗ Corresponding authors at: Department of Clinical Molecular Biology, Gradu-
te  School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670
apan. Tel.: +81 43 226 2139; fax: +81 43 226 2139.
E-mail addresses: kasamatsua@faculty.chiba-u.jp (A. Kasamatsu),
anzawap@faculty.chiba-u.jp (H. Tanzawa).
348-8643/$ – see front matter ©  2011 Japanese Stomatological Society. Published by Els
oi:10.1016/S1348-8643(11)00027-9OSCC is a frequently occurring neoplasm that is usually aggres-
sive and has a poor prognosis. Improvements in speciﬁcity and
sensitivity of diagnosis and disease prognosis depend on the elu-
cidation of the biologic and molecular mechanisms underlying
carcinogenesis [18]. The accumulation of genetic alterations during
oral carcinogenesis is currently explored [19–21].  However, little is
known about the molecular mechanisms of OSCC compared with
other human malignancies.It has been generally accepted that loss of function of the TSG
is a key event during the progression of human malignancies [22].
These genes are thought to encode proteins that negatively regulate
cell growth and thus suppress tumorigenesis. Investigators have
evier Ltd. All rights reserved.
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Table 1
Chromosomes, localized symbol variation, and LOH events.
Location Locus symbol Frequency of LOH Reference
1p36.1 D1S160 73% [15]
1p36.3 TP73 73% [15]
1q31.1 D1S2595 70% [64]
2q32–35 D2S1327 32% [3]
2q36 D2S206 37% [3]
3p13 CL3-373 73% [56]
3p14.2 FHIT 55% [60]
3p21 D3F15S2 81% [58]
3p21.3 MST1 79% [59]
3p22-24 THRB 50% [56]
3p25 RAF1 71% [57]
3q26 SLC2A2 41% [59]
4q25 D4S1573 48% [4]
5q D5S178 52% [5]
5q21 APC 73% [11]
6q25-27 IGF2R 54% [65]
7q31.1 D7S522 56% [6]
8p12, 8p22 D8S87, D8S258 63% [7]
8p21.2 NEFL 33% [66]
8q13-22.1 D8S251 24% [67]
9p21 CDKN2A 68% [68]
9p21 MTAP 53% [8]
9p21-22 IFNA 53% [8]
9p21-22 CDKN2B/CDKN2A 47%, 53% [1,8]
9p24 GATA62F03 86% [69]
10p14-15 KLF6 60% [70]
10p14-15 PFKFB3 55% [70]
10q11.2 Dkk1 50% [71]
10,23 PTEN 27% [72]
10,26.13 DMBT1 23% [9]
11p  HRAS 22% [73]
11q13 INTS2 47% [74]
11q22 D11S35 67% [75]
11q23 APOC3 44% [10]
11q25 D11S912 38% [10]
12q23-24.1 D12S105 32% [67]
13,13.1 BRCA2 33% [76]
13q14.2, 13q32 RB1 67% [77]
13q14.3 D13S273 36% [12]
13q21.33 BRCAX 33% [76]
14q24.2-q32.12 D14S258 54% [78]
15q21 D15S211 62% [69]
16q12-13 D16S541 71% [79]
16q23 BCAR1 35% [80]
17p13 TP53 80% [43]
17p13 HIC1 14% [81]
17q21 TOB1 75% [82]
18q21 D18S46 33% [13]
18q21 DCC 82% [75]
19q12 D19S433 35% [69]
20p11.2 D20S48 28% [14]
20q12-13.1 RPN2 31% [14]
21q11.1 BTG3 60% [16]
21q11.1 D21S236 44% [2]
22q13 D22S274 41% [17]8 A. Kasamatsu et al. / Oral Scie
dentiﬁed genetic alterations associated with OSCCs, such as muta-
ions in the p53 gene [23], adenomatous polyposis coli (APC) gene
11,24], and mutation or hypermethylation of p16 gene [25,26].
herefore, alternations in TSGs are widely accepted to be critical
vents in the multistep process leading to the development of can-
er.
As allelic loss at a certain region of chromosome is thought
o indicate the presence of TSGs, LOH analysis is presently the
ost common method used to identify potential locations for these
enes [27]. Studies based on somatic LOH have already led to the
iscovery of several TSGs, such as the retinoblastoma (Rb) gene,
PC gene [28], and fragile histidine triad (FHIT) gene [29].
The allelotyping studies, including our previous reports, have
hown multiple chromosomal regions in which LOH was frequently
bserved in OSCCs (Fig. 1 and Table 1). This evidence indicates
hat there are a number of TSGs involved in the carcinogenesis
f OSCC. In the present review, we also adopted a computational
ool, Ingenuity Pathway Analysis (IPA) software (Ingenuity Sys-
ems, Mountain View, CA, USA) to identify regulatory networks of
he genes located on loci of LOH in OSCCs.
The aim of this study was to review the current knowledge of
OH in OSCC and to provide the reader with an assessment of their
rognosis and predictive value.
. Oral squamous cell carcinoma
OSCC, accounting for 275,000 new cases and more than 120,000
eaths annually, is the sixth most common malignancy and con-
titutes a major health problem which is associated with severe
orbidity [30–32].  Despite therapeutic and diagnostic advances,
he 5-year survival rate for OSCC remains at about 50% [33–35].
he poor prognosis of OSCC has not improved signiﬁcantly over
he past four decades [31,36]. One of the major causes accounting
or the poor outcome of patients with OSCC is that a great propor-
ion of oral cancers are diagnosed at advanced stages and, therefore,
reated late. Early detection of premalignant or OSCC lesions will
reatly reduce morbidity associated with late disease treatment
nd improve overall patient survival. Indeed, early diagnosis and
reatment of OSCC lead to a mean survival rate of over 80% and a
ood quality of life after treatment [37].
The most important risk factors for the development of OSCC
re tobacco and alcohol [38–41].  However, some patients develop
SCC without risk factors, suggesting that host susceptibility plays
n important role. Therefore, dysregulation of oncogenes and TSGs,
ytogenetic changes, epigenetic changes, and mitochondrial muta-
ions associated with the development of OSCC could be important
lues to preventing this disease [28,41,42].
The development of OSCCs is a multistep process accompanied
y genetic and epigenetic changes, including LOH, gene inactiva-
ion by methylation, and gene ampliﬁcation, all of which can alter
ene expression [43]. Elucidation of the genetic changes leading to
he development of OSCCs will probably result in improved molec-
lar assays for the early diagnosis of, therapy for, and improved
rognosis of this cancer. Thus, understanding the molecular mech-
nisms involved in the initiation and progression to malignancy of
SCC will help to improve its prognosis and in the development of
ew forms of treatment.
. Tumor suppressor genes and loss of heterozygosity
Oncogenes are variations of normal genes (proto-oncogenes)
hat play important roles in normal cells by activating cell signal-
ng or proliferation. These genes become active because of speciﬁc
bnormalities such as gene ampliﬁcation, overexpression, point
utation, insertion mutation, or translocation [44]. Another group22q13.2-13.31 CYB5R3 25% [83]
Bold indicates our previous reports.
of genes involved in cancer development and progression are TSGs
[44]. TSGs have a normal physiological role of retarding cell divi-
sion. TSGs work with the DNA repair system, which makes them
necessary in the maintenance of host genetic stability. TSGs in
mutated form can be passed on as germline heritable DNA defects.
They are the cause of syndromes of genetic predisposition to can-
cer [45]. For example, APC, one of the TSGs, was identiﬁed 10
years ago through its association with an inherited syndrome of
colorectal cancer known as familial adenomatous polyposis coli
(FAP), and was  mutated in the germ-line DNA of patients with FAP.
Somatic mutations or allelic deletions of APC, or both, have also
been described in sporadic colorectal cancer [46].
Inactivation of TSGs causes cells to display one or more pheno-
types of neoplastic growth. Knudson’s deﬁnition [47] of a classical
A. Kasamatsu et al. / Oral Science International 8 (2011) 37– 43 39
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revious reports.
SG requires the inactivation of both alleles of a candidate gene in
umors. Inactivation of these classical TSGs usually occurs either in
he deletion of the one own allele or mutation in the other allele.
owever, a class of TSGs with haploid insufﬁciency, in which one
llele is lost and the remaining allele is haploid sufﬁcient, has been
escribed and these hemizygous TSGs show a tumor-prone pheno-
ype when challenged with carcinogens [46–49].
One of the critical steps for the identiﬁcation of TSGs is LOH anal-
sis [47]. LOH is believed to be one of the key steps to carcinogenesis
f several types of cancer. LOH, caused by a deletion mutation or
oss of a chromosome from a chromosome pair, and identiﬁed by
omparing patterns of polymorphisms in normal and tumor cells carcinoma. Detailed deletion mappings of chromosomes 1–22 are shown. (*) Our
from one individual [50], is observed at many loci in cancers. At
loci showing LOH, two  alleles are observed in normal cells, while
only one allele is detected in tumor cells because the other has
been lost. When this occurs at a TSG locus where one of the alle-
les is already abnormal, it can result in neoplastic transformation
[50–54].
LOH can be identiﬁed in cancers by noting the presence of het-
erozygosity at a genetic locus in an organism’s germline DNA and
the absence of heterozygosity at that locus in the cancer cells. This
is often done using polymorphic markers, such as microsatellites
or single nucleotide polymorphisms, for which the two parents
contributed different alleles [50].
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Table 2
Genetic components in ingenuity networks.
Genes Functions Scorea
1 AEN, APOC3, BAP1, BLZF1, BTG3, CCND2, Cyclin A, DBP, DKK1,  Estrogen
Receptor, FKBP1B, Histone h3, HRAS,  IGF2R,  INPP4A, KCNJ4, LGALS3,
miR-26a/miR-26b, miR-27b/miR-27a, MST1,  P2RX4, PLK2, PPP4R2, PTEN,
RAF1,  RB1, RNASEH1, S100A2, SHISA5, SNRK, THRB, TP53, TP73, VRK1, ZNF175
(1) Cancer
(2) Cell cycle
(3) Cellular growth
(4) Proliferation
24
2  AGTR1, ALDH3A1, APC, BCAR1, CCNE2, CDKN1A, CDKN1C, CDKN2C, COL18A1,
CYB5R3,  Cyclin D, DCC, DMBT1, DNAJB4, E2F1, FHIT, HIC1, ID3, KLF6, LIMA1,
MAP2K3, mir-17, NFkB (complex), NPAT, PFKFB3, PHKA2, RPN2, RRM1, SHC3,
SKP2, SRC, STAT1, TOB1, TRIP6, ZYX
Cell cycle 19
3 APP,  NEFL Cellular assembly and organization 2
4  INTS2,  POLR2C Cellular development 2
5  IFNA, IRF7, MX1  Cellular development 2
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[1–17,53,56–60,63–86]. Here, we compared the status of LOHs
between OSCC and other SCCs, including esophageal cancer, cer-
vical cancer, and lung cancer. Similar to loci of LOH  in OSCC, other
SCCs demonstrated the relationship between LOHs and TSGs, such
Table 3
Gene ontology of genes on LOH loci.
Molecular function p-value Gene, n
Cancer 8.77E−10 to 7.75E−03 19old indicates our previous reports.
a A score > 3 was  considered signiﬁcant.
. Oral squamous cell carcinoma and loss of heterozygosity
.1. LOH loci in OSCC
LOH in OSCC was ﬁrst reported by Howell et al. [55]. It was then
xplored by many investigators. Attempts to establish the rela-
ionship between OSCCs and allele losses at different chromosome
oci have been made. As shown in Fig. 1 and Table 1, we summa-
ized previous articles regarding LOH in OSCCs. Multiple LOHs were
bserved at various loci on almost all chromosomes, except X and
.
Among those chromosomes, highly frequent LOHs were
bserved on chromosome 3 in OSCCs [56–62].  Especially, the short
rm of chromosome 3 (3p) is often deleted in OSCCs [59]. LOH has
een mapped to three distinct regions of loss, 3p13-p21.1, 3p21.3-
23, and 3p25 [56–62].  The region close to 3p14 is a fragile site on
p. At least two or even three TSGs may  be involved on 3p [59]. The
HIT gene, localized to 3p14.2 is altered in OSCC with decreased
r aberrant protein [60] but no mutations and deletions [61,62].
he FHIT protein has dinucleoside triphosphate hydrolase activity.
owever, the relationship between FHIT activity and carcinogene-
is of OSCC is still unclear.
.2. Tumor suppressor genes
A number of downregulations of TSGs were closely related to
he LOH in OSCCs. We  describe here the representative three TSGs,
P73, APC, and CDKN2A.
.2.1. TP73
Much evidence also suggests that TP73 acts as a TSG and is
bnormally expressed in many human cancers. TP73 gene, with
 signiﬁcant homology to p53, was located just at the D1S468 locus
f 1p36.3. Allelic loss of TP73 in 41 OSCCs had a frequency of 73%
15]. And also, TP73 was inactivated by the methylation-dependent
ilencing of this gene, and was associated with the tumor progres-
ion of human OSCC.
.2.2. APC
APC is located on chromosome 5q21-q22 and is associated with
he development not only of FAP but also of cancers in digestive
rgans. The role of APC in tumorigenesis is associated with intracy-
oplasmic accumulation of beta-catenin in response to carcinogenic
timuli, as the WNT  signal. LOH of the APC was detected in 72.7%
f OSCCs [11], and associated frequently with heavy smokers and
rinkers, and in tumors with p53 mutations and human papilloma
irus infection, suggesting that abnormalities in APC were closely
elated to the etiology and development of OSCC.4.2.3. CDKN2A (p16)
The ﬁnding of frequent homozygous deletions in a wide vari-
ety of cancer cell lines focused attention upon the CDKN2A gene, a
negative regulator of cell cycle progression located at chromosome
9p21. LOH of the CDKN2A was detected in 53% of OSCCs [8],  and
2 of 50 (4%) OSCCs had nonsense mutations of the CDKN2A. It is
unclear whether all of the allelic loss events at 9p21 in oral cancer
are associated with CDKN2A inactivation.
4.3. Network and gene ontology analyses of genes located on LOH
loci in OSCC
From 44 reports of OSCC-associated LOH, we extracted 28 down-
regulated genes in OSCCs (Table 1). We  carried out network analysis
on the 28 genes using the IPA tool to investigate if these genes
interact biologically. Of the 28 genes, 27 were mapped to genetic
networks as deﬁned. These networks described functional rela-
tionships between gene products based on known interactions in
the literature. Five identiﬁed networks were associated with the
functions of cancer, cell cycle, cellular growth, and proliferation,
etc. (Table 2). We  also performed gene ontology analysis using
the IPA tool. Five functions were identiﬁed as high-level functions
(Table 3). Of them, the top function was the cancer-related function
(Table 3, p = 8.77E−10 to 7.75E−03). Furthermore, to investigate the
network of 19 cancer-related genes (Table 3), we performed net-
work analysis using the IPA tool. Consequently, we found a major
network (Fig. 2) including 13 cancer-related genes (Table 4). The
shaded genes are those identiﬁed from previous OSCC-associated
LOH studies, and the others are associated with the regulated
genes based on network. These results indicated that carcinogen-
esis would be correlated with not only LOH but also networks of
several cancer-related genes.
4.4. Comparison between LOH in OSCC and that in other SCCs
Some groups reviewed the LOH studies in other SCCsCellular development 6.39E−9 to 7.75E−03 16
Cell  death 2.33E−8 to 7.75E−03 15
Cell  cycle 1.29E−10 to 7.75E−03 14
Cell  morphology 1.18E−7 to 7.75E−03 9
A. Kasamatsu et al. / Oral Science International 8 (2011) 37– 43 41
Fig. 2. The network associated with cancer. The major network shown is associated wi
erozygosity analysis and the others are associated with the regulated genes based on the
indicated.
Table  4
Thirteen cancer-related genes.
Symbol Description
APOC3 Apolipoprotein C-II
BTG3 BTG family, member 3
CCND2 Cyclin D2
DKK1 Dickkopf homolog 1
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog
IGF2R Insulin-like growth factor 2 receptor
MST1 Macrophage stimulating 1
PTEN Phosphatase and tensin homolog
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1
RB1 Retinoblastoma 1
THRB Thyroid hormone receptor, beta
a
i
5
O
t
r
l
m
i
m
D
[TP53 Tumor protein p53
TP73 Tumor protein p73
s TP53, TP73, and RB1. Therefore, OSCC-speciﬁc LOH loci were not
dentiﬁed so far.
. Conclusions
This review aimed to explore current knowledge about LOHs in
SCC, which develops after a long carcinogenesis cycle and mul-
iple stages. A number of TSGs are involved in this process. As a
esult, allele loss chromosome regions, where candidate TSGs are
ocated, were important in terms of the progress of OSCC. This sum-
ary of LOHs would be helpful for monitoring of clinical behaviors
n OSCCs; e.g., we had revealed the relationship between the chro-
osome aberrant in OSCCs and their prognosis using circulating
NA in the peripheral blood [63].
[th cancer (p = 8.77E−10 to 7.75E−03). Shaded genes are identiﬁed by loss of het-
 Ingenuity Pathway Analysis network analysis. The meaning of the node shapes is
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